Piper Jaffray downgraded Arrowhead Research (NYSE:ARWR) from Overweight to Neutral in a statement released today.
- Updated: November 30, 2016
Just yesterday Arrowhead Research (NYSE:ARWR) traded -1.57% lower at $1.47. Arrowhead Research’s 50-day moving average is $5.64 and its 200-day moving average is $6.10. The last closing price is down -28.02% from the 200-day moving average, compared to the Standard & Poor's 500 Index which has decreased -0.03% over the same time period. 19,940 shares of ARWR traded hands, down from an average trading volume of 1,021,960
Piper Jaffray has downgraded Arrowhead Research (NYSE:ARWR) from Overweight to Neutral in a report released on Wednesday November 30, 2016.
Previously on 9/25/2015, Piper Jaffray reported on Arrowhead Research (NYSE:ARWR) increased the target price from $12.00 to $20.00. At the time, this indicated a possible upside of 1.65%.
Recent Performance Chart
Arrowhead Research has 52 week low of $3.07 and a 52 week high of $8.22 and has a market capitalization of $0.
In addition to Piper Jaffray reporting its stock price target, a total of 3 brokers have issued a research note on the company. The average stock price target is $8.92 with 0 brokers rating the stock a strong buy, 2 brokers rating the stock a buy, 2 brokers rating the stock a hold, 0 brokers rating the stock a underperform, and finally 0 brokers rating the stock a sell.
Brief Synopsis On Arrowhead Research (NYSE:ARWR)
Arrowhead Pharmaceuticals, Inc., formerly Arrowhead Research Corporation, is a biopharmaceutical company. The Company is engaged in developing RiboNucleic Acid interference (RNAi) therapeutics. Its products include ARC-520, ARC-521, ARC-AAT, ARC-F12, ARC-HIF2 and ARC-LPA. ARC-520 is designed to treat chronic hepatitis B virus (HBV) infection. ARC-AAT is an unlocked nucleobase analog containing RNAi-based therapeutic for the treatment of liver disease associated with alpha-1 antitrypsin deficiency (AATD). Its Dynamic Polyconjugate platform is an RNAi delivery system that promotes high levels of target gene knockdown. ARC-F12 is an RNAi-based therapeutic designed to reduce the production of factor 12 for providing a prophylactic treatment for hereditary angioedema and thromboembolic diseases. ARC-LPA is an RNAi-based therapeutic designed to reduce production of apolipoprotein A. ARC-HIF2 is an RNAi-based therapeutic designed to reduce the production of hypoxia-inducible factor 2a.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.